Acrivon Therapeutics appointed Michaela Levin as chief business officer, effective Aug. 31, 2026.
Levin most recently served as vice president of business development at Recursion, formerly Exscientia, an AI platform company.
She previously held business development roles at Editas Medicine, Ovid Therapeutics, Constellation Pharmaceuticals, Harvard University and Mass General Brigham.
ACRV•
